The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Try the newly designed Company Pages!
Switch now

Gilead Sciences

  • GILD
  • NASDAQ
  • Consumer Products
  • Latest 89.84
  • Currency US$
  • Change -0.70
  • Percent Change -0.773 %
  • Volume 13,057,569
  • Fri Jul 25, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 90.68
  • Previous Close 90.54
  • High 90.78
  • Low 88.70
  • Bidx4 89.50
  • Askx18 89.55
  • 52-week High07/24 92.97
  • 52-week Low08/15 55.96
  • Beta 1.464
  • Market Cap 138,194.58M
  • EPS 2.88
  • P/E 31.194
  • Forward P/E 10.61
  • PEG 0.48
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $13,669,010,000
  • Earnings $4,580,030,000
  • Return on Equity 36.00%

Cash Flow

  • Cash Flow --
  • Cash $6,404,150,000
  • Current Ratio 2.19

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $28,077,690,000
  • Liabilities $14,375,500,000
  • Liabilities-to-Equity Ratio 1.05

Price Ratios

  • Price to Sales 10.11
  • Price to Book 10.09
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Jul 23 $1.61 Nov 4 $1.40
Surprises Jul 23 44.10% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Jul 25, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.

Related Securities
Symbol Type Latest % Chg

Officers

  • John C. Martin, Ph.D. Chairman and C.E.O.
  • Robin L. Washington Exec. V.P. and C.F.O
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

333 LAKESIDE DR
FOSTER CITY, CA
94404

Phone: (650)-574-3000
Fax: (650)-5789264

investor_relations@gilead.com
www.gilead.com

Ideas & Discussion

Live Discussion of GILD on StockTwits
The Globe and Mail has
updated our Company Pages
Switch to the newly designed Company Pages format today for a more in-depth look at the companies you're following and pages that are easier to navigate. If you prefer the old layout after trying the new Company Pages, you can switch back anytime.